Tech Company Financing Transactions
Atavistik Bio Funding Round
On 3/5/2026, Atavistik Bio raised $40 million in Series B funding from Lux Capital, Nextech Invest and RA Capital Management.
Transaction Overview
Company Name
Announced On
3/5/2026
Transaction Type
Venture Equity
Amount
$40,000,000
Round
Series B
Investors
Proceeds Purpose
Atavistik Bio will use the proceeds from the upsized Series B financing to fund clinical development of ATV-1601, a potential best-in-class AKT1-selective oral inhibitor for HHT, and its JAK2 V617F mutant-selective inhibitor program for MPNs through clinical proof of concept.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
Undisclosed
Cambridge, MA 02139
USA
Cambridge, MA 02139
USA
Phone
Undisclosed
Website
Email Address
Overview
Atavistik Bio's high-throughput platform for the unbiased identification of metabolite-protein interactions, will enable us to discover first-in-class drugs inspired and empowered by nature's own mechanisms of allosteric control.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
John Josey
Founder
Ralph DeBerardinis
Founder
Jared Rutter
President
Marion Dorsch
Browse more venture capital transactions:
Prev: 3/5/2026: Levitate venture capital transaction
Next: 3/5/2026: Cheer Games venture capital transaction
Share this article
Where The Data Comes From
We report on tech company VC transactions. VC investment data records reported here are sourced from company press releases and news coverage. The data is sourced from VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs